Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) have earned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $37.56.

Several research firms have recently weighed in on NTLA. HC Wainwright began coverage on shares of Intellia Therapeutics in a report on Wednesday, March 5th. They set a “buy” rating and a $30.00 price objective for the company. Oppenheimer dropped their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating for the company in a report on Monday, January 13th. BMO Capital Markets dropped their price objective on shares of Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a report on Friday, January 10th. Chardan Capital dropped their price objective on shares of Intellia Therapeutics from $91.00 to $68.00 and set a “buy” rating for the company in a report on Friday, February 28th. Finally, Citigroup raised their price target on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, February 28th.

Insider Transactions at Intellia Therapeutics

In other news, CEO John M. Leonard sold 26,807 shares of Intellia Therapeutics stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold a total of 29,000 shares of company stock valued at $352,551 over the last three months. 3.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in shares of Intellia Therapeutics during the fourth quarter worth $25,000. Sterling Capital Management LLC raised its holdings in shares of Intellia Therapeutics by 866.2% during the fourth quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after acquiring an additional 2,867 shares during the period. Whipplewood Advisors LLC acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth $40,000. Resona Asset Management Co. Ltd. acquired a new stake in shares of Intellia Therapeutics during the fourth quarter worth $43,000. Finally, KBC Group NV raised its holdings in shares of Intellia Therapeutics by 37.3% during the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock worth $77,000 after acquiring an additional 1,020 shares during the period. 88.77% of the stock is owned by institutional investors.

Intellia Therapeutics Stock Down 6.5 %

NASDAQ:NTLA opened at $8.70 on Friday. Intellia Therapeutics has a 12-month low of $8.30 and a 12-month high of $28.54. The firm has a market capitalization of $900.60 million, a PE ratio of -1.60 and a beta of 1.97. The firm has a 50-day moving average price of $10.11 and a 200 day moving average price of $14.33.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.